Acadia Pharmaceuticals (ACAD) Equity Average (2011 - 2026)

Acadia Pharmaceuticals' Equity Average history runs 16 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Equity Average rose 65.25% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 65.25% YoY), while the FY2025 annual figure was $980.1 million, up 68.32% from the prior year.
• Equity Average was $1.2 billion for Q1 2026 at Acadia Pharmaceuticals, up from $1.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.2 billion in Q1 2026 to a low of $379.0 million in Q3 2023.
• Historically, Equity Average has averaged $599.2 million across 5 years, with a median of $490.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Equity Average dropped 25.43% in 2022, then surged 67.23% in 2025.
• A 5-year view of Equity Average shows it stood at $413.0 million in 2022, then declined by 3.89% to $397.0 million in 2023, then surged by 65.0% to $655.0 million in 2024, then surged by 63.72% to $1.1 billion in 2025, then rose by 15.42% to $1.2 billion in 2026.
• The last three Equity Average figures came in at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $869.8 million (Q3 2025), per Business Quant data.